retatrutide update october 2025 is the most significant weight-loss pharmaceutical currently in clinical development., Phase 3 TRIUMPH-4 trial results (published December 2025) showed average body weight reduction of Retatrutide Timeline: Week-by-Week Results (48

TB-500 (Thymosin Beta-4) : A regenerative peptide that enhances cell migration, reduces inflammation, and accelerates recovery in soft tissues

Now, a new study published in Led by researchers from the University of Pennsylvania, the study examined more than 400,000 Reddit posts from nearly 70,000 users discussing GLP-1 receptor agonists, including semaglutide and tirzepatide

A 1999 rat full-thickness wound study reported accelerated wound closure and changes in collagen and angiogenesis-related measurements after full-length thymosin beta-4 exposure

One looked at the effect of BPC-157 on bladder pain (12 people) and the other looked at knee pain (16 people)